Leukemia Therapeutics Market 2027 By Type, Treatment Type, Mode of Administration, Molecule Type, Gender and Geopgraphy | The Insight Partners

Leukemia Therapeutics Market to 2027 - Global Analysis and Forecasts by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Geopgraphy

Report Code: TIPRE00006430 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming
MARKET INTRODUCTION

Leukemia is cancer of bone marrow and white blood cells. When a person has leukemia, the body creates too many white blood cells. Conventional treatments to fight leukemia include chemotherapy, biological therapy, targeted therapy, radiation therapy, and others.

MARKET DYNAMICS

Considerable number of treatment options available for the treatment of Chronic myeloid leukemia (CML) and high incidence rate of CML are significantly driving the growth of this market.

MARKET SCOPE

The "Global Leukemia Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the medical industry with a special focus on the global market trend analysis. The report aims to provide an overview of leukemia therapeutics market with detailed market segmentation by type, treatment, mode of administration, molecule type, gender and geography. The global leukemia therapeutics market is expected to witness high growth during the forecast period. The report provides key information on the market status of the leading leukemia therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global leukemia therapeutics market is segmented on the basis of type, treatment, mode of administration, molecule type, gender and geography. Based on type, the market is segmented as, CLL, ALL, CML, AML. Treatment Type is further segmented into chemotherapy & targeted drugs by CLL, ALL, CML, AML. By mode of administration (oral, injectable), molecule type (small molecules, biologics) and gender



REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global leukemia therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The leukemia therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting leukemia therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the leukemia therapeutics market in these regions.


MARKET PLAYERS


The reports cover key developments in the leukemia therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from leukemia therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for leukemia therapeutics market in the global market. Below mentioned is the list of few companies engaged in the leukemia therapeutics market.

The report also includes the profiles of key leukemia therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Novartis AG
  •  AbbVie
  •  Bristol-Myers Squibb
  •  F. Hoffmann-La Roche
  •  Sanofi
  •  Pfizer
  •  Amgen
  •  Gilead Sciences
  •  Takeda
  •  Celgene
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Leukemia Therapeutics Market - By Type
1.3.2 Leukemia Therapeutics Market - By Treatment
1.3.3 Leukemia Therapeutics Market - By Molecule Type
1.3.4 Leukemia Therapeutics Market - By Mode of Administration
1.3.5 Leukemia Therapeutics Market - By Gender
1.3.6 Leukemia Therapeutics Market - By Region
1.3.6.1 By Country

2. KEY TAKEAWAYS


3. RESEARCH METHODOLOGY


4. LEUKEMIA THERAPEUTICS MARKET LANDSCAPE

4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. LEUKEMIA THERAPEUTICS MARKET - KEY MARKET DYNAMICS

5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. LEUKEMIA THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS

6.1. LEUKEMIA THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. LEUKEMIA THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - TYPE

7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. CHRONIC MYELOID LEUKEMIA
7.3.1. Overview
7.3.2. Chronic Myeloid Leukemia Market Forecast and Analysis
7.4. CHRONIC LYMPHOCYTIC LEUKEMIA
7.4.1. Overview
7.4.2. Chronic Lymphocytic Leukemia Market Forecast and Analysis
7.5. ACUTE LYMPHOCYTIC LEUKEMIA
7.5.1. Overview
7.5.2. Acute Lymphocytic Leukemia Market Forecast and Analysis
7.6. ACUTE MYELOID LEUKEMIA
7.6.1. Overview
7.6.2. Acute Myeloid Leukemia Market Forecast and Analysis

8. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT

8.1. OVERVIEW
8.2. TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. TARGETED DRUGS AND IMMUNOTHERAPY
8.3.1. Overview
8.3.2. Targeted Drugs And Immunotherapy Market Forecast and Analysis
8.4. CHEMOTHERAPY
8.4.1. Overview
8.4.2. Chemotherapy Market Forecast and Analysis

9. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - MOLECULE TYPE

9.1. OVERVIEW
9.2. MOLECULE TYPE MARKET FORECASTS AND ANALYSIS
9.3. SMALL MOLECULES
9.3.1. Overview
9.3.2. Small Molecules Market Forecast and Analysis
9.4. BIOLOGICS
9.4.1. Overview
9.4.2. Biologics Market Forecast and Analysis

10. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - MODE OF ADMINISTRATION

10.1. OVERVIEW
10.2. MODE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
10.3. ORAL MODE
10.3.1. Overview
10.3.2. Oral Mode Market Forecast and Analysis
10.4. INJECTABLE MODE
10.4.1. Overview
10.4.2. Injectable Mode Market Forecast and Analysis

11. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - GENDER

11.1. OVERVIEW
11.2. GENDER MARKET FORECASTS AND ANALYSIS
11.3. MALES
11.3.1. Overview
11.3.2. Males Market Forecast and Analysis
11.4. FEMALES
11.4.1. Overview
11.4.2. Females Market Forecast and Analysis

12. LEUKEMIA THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS

12.1. NORTH AMERICA
12.1.1 North America Leukemia Therapeutics Market Overview
12.1.2 North America Leukemia Therapeutics Market Forecasts and Analysis
12.1.3 North America Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.1.4 North America Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.1.5 North America Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.1.6 North America Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.1.7 North America Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.1.8 North America Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.1.8.1 United States Leukemia Therapeutics Market
12.1.8.1.1 United States Leukemia Therapeutics Market by Type
12.1.8.1.2 United States Leukemia Therapeutics Market by Treatment
12.1.8.1.3 United States Leukemia Therapeutics Market by Molecule Type
12.1.8.1.4 United States Leukemia Therapeutics Market by Mode of Administration
12.1.8.1.5 United States Leukemia Therapeutics Market by Gender
12.1.8.2 Canada Leukemia Therapeutics Market
12.1.8.2.1 Canada Leukemia Therapeutics Market by Type
12.1.8.2.2 Canada Leukemia Therapeutics Market by Treatment
12.1.8.2.3 Canada Leukemia Therapeutics Market by Molecule Type
12.1.8.2.4 Canada Leukemia Therapeutics Market by Mode of Administration
12.1.8.2.5 Canada Leukemia Therapeutics Market by Gender
12.1.8.3 Mexico Leukemia Therapeutics Market
12.1.8.3.1 Mexico Leukemia Therapeutics Market by Type
12.1.8.3.2 Mexico Leukemia Therapeutics Market by Treatment
12.1.8.3.3 Mexico Leukemia Therapeutics Market by Molecule Type
12.1.8.3.4 Mexico Leukemia Therapeutics Market by Mode of Administration
12.1.8.3.5 Mexico Leukemia Therapeutics Market by Gender
12.2. EUROPE
12.2.1 Europe Leukemia Therapeutics Market Overview
12.2.2 Europe Leukemia Therapeutics Market Forecasts and Analysis
12.2.3 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.2.4 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.2.5 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.2.6 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.2.7 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.2.8 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.2.8.1 Germany Leukemia Therapeutics Market
12.2.8.1.1 Germany Leukemia Therapeutics Market by Type
12.2.8.1.2 Germany Leukemia Therapeutics Market by Treatment
12.2.8.1.3 Germany Leukemia Therapeutics Market by Molecule Type
12.2.8.1.4 Germany Leukemia Therapeutics Market by Mode of Administration
12.2.8.1.5 Germany Leukemia Therapeutics Market by Gender
12.2.8.2 France Leukemia Therapeutics Market
12.2.8.2.1 France Leukemia Therapeutics Market by Type
12.2.8.2.2 France Leukemia Therapeutics Market by Treatment
12.2.8.2.3 France Leukemia Therapeutics Market by Molecule Type
12.2.8.2.4 France Leukemia Therapeutics Market by Mode of Administration
12.2.8.2.5 France Leukemia Therapeutics Market by Gender
12.2.8.3 Italy Leukemia Therapeutics Market
12.2.8.3.1 Italy Leukemia Therapeutics Market by Type
12.2.8.3.2 Italy Leukemia Therapeutics Market by Treatment
12.2.8.3.3 Italy Leukemia Therapeutics Market by Molecule Type
12.2.8.3.4 Italy Leukemia Therapeutics Market by Mode of Administration
12.2.8.3.5 Italy Leukemia Therapeutics Market by Gender
12.2.8.4 Spain Leukemia Therapeutics Market
12.2.8.4.1 Spain Leukemia Therapeutics Market by Type
12.2.8.4.2 Spain Leukemia Therapeutics Market by Treatment
12.2.8.4.3 Spain Leukemia Therapeutics Market by Molecule Type
12.2.8.4.4 Spain Leukemia Therapeutics Market by Mode of Administration
12.2.8.4.5 Spain Leukemia Therapeutics Market by Gender
12.2.8.5 United Kingdom Leukemia Therapeutics Market
12.2.8.5.1 United Kingdom Leukemia Therapeutics Market by Type
12.2.8.5.2 United Kingdom Leukemia Therapeutics Market by Treatment
12.2.8.5.3 United Kingdom Leukemia Therapeutics Market by Molecule Type
12.2.8.5.4 United Kingdom Leukemia Therapeutics Market by Mode of Administration
12.2.8.5.5 United Kingdom Leukemia Therapeutics Market by Gender
12.3. ASIA-PACIFIC
12.3.1 Asia-Pacific Leukemia Therapeutics Market Overview
12.3.2 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis
12.3.3 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.3.4 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.3.5 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.3.6 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.3.7 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.3.8 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.3.8.1 Australia Leukemia Therapeutics Market
12.3.8.1.1 Australia Leukemia Therapeutics Market by Type
12.3.8.1.2 Australia Leukemia Therapeutics Market by Treatment
12.3.8.1.3 Australia Leukemia Therapeutics Market by Molecule Type
12.3.8.1.4 Australia Leukemia Therapeutics Market by Mode of Administration
12.3.8.1.5 Australia Leukemia Therapeutics Market by Gender
12.3.8.2 China Leukemia Therapeutics Market
12.3.8.2.1 China Leukemia Therapeutics Market by Type
12.3.8.2.2 China Leukemia Therapeutics Market by Treatment
12.3.8.2.3 China Leukemia Therapeutics Market by Molecule Type
12.3.8.2.4 China Leukemia Therapeutics Market by Mode of Administration
12.3.8.2.5 China Leukemia Therapeutics Market by Gender
12.3.8.3 India Leukemia Therapeutics Market
12.3.8.3.1 India Leukemia Therapeutics Market by Type
12.3.8.3.2 India Leukemia Therapeutics Market by Treatment
12.3.8.3.3 India Leukemia Therapeutics Market by Molecule Type
12.3.8.3.4 India Leukemia Therapeutics Market by Mode of Administration
12.3.8.3.5 India Leukemia Therapeutics Market by Gender
12.3.8.4 Japan Leukemia Therapeutics Market
12.3.8.4.1 Japan Leukemia Therapeutics Market by Type
12.3.8.4.2 Japan Leukemia Therapeutics Market by Treatment
12.3.8.4.3 Japan Leukemia Therapeutics Market by Molecule Type
12.3.8.4.4 Japan Leukemia Therapeutics Market by Mode of Administration
12.3.8.4.5 Japan Leukemia Therapeutics Market by Gender
12.3.8.5 South Korea Leukemia Therapeutics Market
12.3.8.5.1 South Korea Leukemia Therapeutics Market by Type
12.3.8.5.2 South Korea Leukemia Therapeutics Market by Treatment
12.3.8.5.3 South Korea Leukemia Therapeutics Market by Molecule Type
12.3.8.5.4 South Korea Leukemia Therapeutics Market by Mode of Administration
12.3.8.5.5 South Korea Leukemia Therapeutics Market by Gender
12.4. MIDDLE EAST AND AFRICA
12.4.1 Middle East and Africa Leukemia Therapeutics Market Overview
12.4.2 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis
12.4.3 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.4.4 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.4.5 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.4.6 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.4.7 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.4.8 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.4.8.1 South Africa Leukemia Therapeutics Market
12.4.8.1.1 South Africa Leukemia Therapeutics Market by Type
12.4.8.1.2 South Africa Leukemia Therapeutics Market by Treatment
12.4.8.1.3 South Africa Leukemia Therapeutics Market by Molecule Type
12.4.8.1.4 South Africa Leukemia Therapeutics Market by Mode of Administration
12.4.8.1.5 South Africa Leukemia Therapeutics Market by Gender
12.4.8.2 Saudi Arabia Leukemia Therapeutics Market
12.4.8.2.1 Saudi Arabia Leukemia Therapeutics Market by Type
12.4.8.2.2 Saudi Arabia Leukemia Therapeutics Market by Treatment
12.4.8.2.3 Saudi Arabia Leukemia Therapeutics Market by Molecule Type
12.4.8.2.4 Saudi Arabia Leukemia Therapeutics Market by Mode of Administration
12.4.8.2.5 Saudi Arabia Leukemia Therapeutics Market by Gender
12.4.8.3 U.A.E Leukemia Therapeutics Market
12.4.8.3.1 U.A.E Leukemia Therapeutics Market by Type
12.4.8.3.2 U.A.E Leukemia Therapeutics Market by Treatment
12.4.8.3.3 U.A.E Leukemia Therapeutics Market by Molecule Type
12.4.8.3.4 U.A.E Leukemia Therapeutics Market by Mode of Administration
12.4.8.3.5 U.A.E Leukemia Therapeutics Market by Gender
12.5. SOUTH AND CENTRAL AMERICA
12.5.1 South and Central America Leukemia Therapeutics Market Overview
12.5.2 South and Central America Leukemia Therapeutics Market Forecasts and Analysis
12.5.3 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.5.4 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.5.5 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.5.6 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.5.7 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.5.8 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.5.8.1 Brazil Leukemia Therapeutics Market
12.5.8.1.1 Brazil Leukemia Therapeutics Market by Type
12.5.8.1.2 Brazil Leukemia Therapeutics Market by Treatment
12.5.8.1.3 Brazil Leukemia Therapeutics Market by Molecule Type
12.5.8.1.4 Brazil Leukemia Therapeutics Market by Mode of Administration
12.5.8.1.5 Brazil Leukemia Therapeutics Market by Gender
12.5.8.2 Argentina Leukemia Therapeutics Market
12.5.8.2.1 Argentina Leukemia Therapeutics Market by Type
12.5.8.2.2 Argentina Leukemia Therapeutics Market by Treatment
12.5.8.2.3 Argentina Leukemia Therapeutics Market by Molecule Type
12.5.8.2.4 Argentina Leukemia Therapeutics Market by Mode of Administration
12.5.8.2.5 Argentina Leukemia Therapeutics Market by Gender

13. INDUSTRY LANDSCAPE

13.1. MERGERS AND ACQUISITIONS
13.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
13.3. NEW PRODUCT LAUNCHES
13.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

14. LEUKEMIA THERAPEUTICS MARKET, KEY COMPANY PROFILES

14.1. NOVARTIS AG
14.1.1. Key Facts
14.1.2. Business Description
14.1.3. Products and Services
14.1.4. Financial Overview
14.1.5. SWOT Analysis
14.1.6. Key Developments
14.2. ABBVIE
14.2.1. Key Facts
14.2.2. Business Description
14.2.3. Products and Services
14.2.4. Financial Overview
14.2.5. SWOT Analysis
14.2.6. Key Developments
14.3. BRISTOL-MYERS SQUIBB
14.3.1. Key Facts
14.3.2. Business Description
14.3.3. Products and Services
14.3.4. Financial Overview
14.3.5. SWOT Analysis
14.3.6. Key Developments
14.4. F. HOFFMANN-LA ROCHE
14.4.1. Key Facts
14.4.2. Business Description
14.4.3. Products and Services
14.4.4. Financial Overview
14.4.5. SWOT Analysis
14.4.6. Key Developments
14.5. SANOFI
14.5.1. Key Facts
14.5.2. Business Description
14.5.3. Products and Services
14.5.4. Financial Overview
14.5.5. SWOT Analysis
14.5.6. Key Developments
14.6. PFIZER
14.6.1. Key Facts
14.6.2. Business Description
14.6.3. Products and Services
14.6.4. Financial Overview
14.6.5. SWOT Analysis
14.6.6. Key Developments
14.7. AMGEN
14.7.1. Key Facts
14.7.2. Business Description
14.7.3. Products and Services
14.7.4. Financial Overview
14.7.5. SWOT Analysis
14.7.6. Key Developments
14.8. GILEAD SCIENCES
14.8.1. Key Facts
14.8.2. Business Description
14.8.3. Products and Services
14.8.4. Financial Overview
14.8.5. SWOT Analysis
14.8.6. Key Developments
14.9. TAKEDA
14.9.1. Key Facts
14.9.2. Business Description
14.9.3. Products and Services
14.9.4. Financial Overview
14.9.5. SWOT Analysis
14.9.6. Key Developments
14.10. CELGENE
14.10.1. Key Facts
14.10.2. Business Description
14.10.3. Products and Services
14.10.4. Financial Overview
14.10.5. SWOT Analysis
14.10.6. Key Developments

15. APPENDIX

15.1. ABOUT THE INSIGHT PARTNERS
15.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis AG
2. AbbVie
3. Bristol-Myers Squibb
4. F. Hoffmann-La Roche
5. Sanofi
6. Pfizer
7. Amgen
8. Gilead Sciences
9. Takeda
10. Celgene